Program Structure

Module 1: Why mRNA Vaccines Changed the Game

• How vaccine platforms differ: inactivated, subunit, viral vector, mRNA (overview).
• What mRNA vaccines do inside the body: antigen expression and immune priming.
• Speed and adaptability: why sequence-based platforms scale fast.
• Limitations: stability, storage, equity, and manufacturing constraints.

Module 2: mRNA Biology Essentials for Vaccine Design

• mRNA structure: 5’ cap, UTRs, coding region, poly(A) tail.
• Translation and antigen presentation: MHC I/II pathway concept.
• Innate immune sensing: how mRNA triggers immune pathways (and why modification helps).
• Self-amplifying RNA (saRNA) concept and how it differs from standard mRNA.

Module 3: Antigen Selection & Sequence Design

• Choosing the antigen: protective epitopes, conserved regions, variant risks.
• Sequence optimization: codon optimization and expression efficiency (concept).
• Stabilizing antigens (concept): structure-guided antigen engineering overview.
• Designing for variants: multivalent and updated-sequence strategies.

Module 4: In Vitro Transcription (IVT) & Manufacturing Workflow

• Core production steps: template DNA → IVT → capping → purification.
• Removing impurities: dsRNA and residuals (why purity matters).
• Scale-up considerations: yield, consistency, contamination control.
• GMP mindset: documentation, batch records, and change control basics.

Module 5: Delivery Systems & LNP Formulation

• Why delivery is essential: protecting mRNA and enabling cell uptake.
• LNP components overview: ionizable lipid, cholesterol, phospholipid, PEG-lipid.
• Formulation parameters: particle size, encapsulation efficiency, stability (concept).
• Administration routes and biodistribution considerations (overview).

Module 6: Quality Control, CQAs & Release Testing (Conceptual + Practical)

• Critical quality attributes (CQAs): identity, purity, potency, safety, stability.
• Typical tests overview: RNA integrity, endotoxin, sterility, particle size, encapsulation.
• Potency concepts: expression-based assays and immune readouts (overview).
• Stability studies: storage conditions and shelf-life logic.

Module 7: Preclinical Evaluation & Immunogenicity

• Preclinical goals: safety signals and immune response profiling.
• Neutralizing antibodies and T-cell responses: what matters and why.
• Dose finding and boosting strategies (overview).
• Translational caution: animal-to-human differences and realistic interpretation.

Module 8: Clinical Development & Safety Monitoring

• Clinical trial phases: Phase I/II/III and endpoints (immunogenicity, efficacy, safety).
• Adverse event monitoring: short-term AEs vs rare events (PV basics).
• Regulatory decision logic: benefit-risk assessment and evidence strength.
• Post-authorization surveillance: real-world effectiveness and safety signals.

Module 9: Implementation at Scale (Public Health & Operations)

• Cold chain and logistics: storage, transport, and site readiness.
• Prioritization strategies: high-risk groups, outbreak response, seasonal deployment.
• Vaccine confidence: communication, misinformation handling, trust-building.
• Equity considerations: access, affordability, and global distribution challenges.

Module 10: Future Directions of mRNA Platforms

• mRNA beyond infectious disease: cancer vaccines and personalized immunotherapy (overview).
• Combination platforms: mRNA + adjuvants, multiepitope strategies.
• Next-gen delivery: improved stability, thermostable formulations (concept).
• Manufacturing innovation: modular facilities and rapid scale-up strategies.

Final Project

• Create an mRNA Vaccine Development or Implementation Blueprint.
• Choose one track:
  • Development Track: antigen choice, sequence plan, manufacturing steps, QC plan, and trial outline.
  • Implementation Track: rollout plan, cold chain design, site workflow, safety monitoring, and communication strategy.
• Example projects: mRNA vaccine plan for an emerging virus, booster strategy for variants, rollout blueprint for a district-wide campaign, oncology mRNA vaccine concept for a tumor antigen.